Sartorius AG (SSSGY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 81.70 means the share price is 81.70 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $15.2B is the value of all shares combined. Beta 1.51: the stock has moved about 51% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSartorius AG (SSSGY) trades at $43.93. Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories. Market cap: $15.2B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SSSGY: SSSGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSSGY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SSSGY: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Sartorius AG (SSSGY) Healthcare & Pipeline Overview
Sartorius AG, a German-based company, provides bioprocess solutions and lab products, serving the biopharmaceutical industry and research labs globally. With a focus on innovative technologies for drug development and manufacturing, Sartorius competes with companies like ALBBY and BDUUY in the medical instruments and supplies sector, demonstrating a commitment to advancing life sciences.
What Is the Investment Thesis for SSSGY?
Sartorius AG presents a notable research candidate within the bioprocessing and lab solutions sector. With a current P/E ratio of 81.70 and a profit margin of 4.4%, the company's growth is underpinned by the increasing demand for biopharmaceutical products and advanced laboratory technologies. Key value drivers include the expansion of its product portfolio, strategic acquisitions, and penetration into emerging markets. Upcoming catalysts include the continued development of innovative bioprocessing solutions and expansion of services. Potential risks include intense competition, currency fluctuations, and regulatory changes in the healthcare sector. The company's high beta of 1.51 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
SSSGY Key Highlights
Market capitalization of $15.2B reflects Sartorius AG's significant presence in the bioprocessing and lab solutions market.
- A P/E ratio of 81.70 indicates a premium valuation, potentially reflecting investor expectations of future growth.
- Gross margin of 46.3% demonstrates the company's ability to maintain profitability in a competitive market.
- Dividend yield of 0.35% provides a modest income stream for investors.
- Beta of 1.51 suggests higher volatility compared to the market, potentially offering higher returns but also greater risk.
Who Are SSSGY's Competitors?
SSSGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALBBY Alibaba Health Information Technology Limited | $7.93 | +2.12% | $6.39B | — |
| BDUUY Bangkok Dusit Medical Services Public Company Limited | $23.30 | 0.00% | $9.26B | — |
| BMXMF bioMérieux S.A. | $86.11 | 0.00% | $10.2B | — |
| CHEOF Cochlear Limited | $98.25 | +1.15% | $6.43B | — |
| BAX Baxter International Inc. | $24.18 | -0.86% | $12.5B | 535-pillar |
| COO The Cooper Companies, Inc. | $53.74 | -0.79% | $10.5B | 385-pillar |
| AVTR Avantor, Inc. | $14.88 | -2.43% | $10.1B | 555-pillar |
| WST West Pharmaceutical Services, Inc. | $345.48 | +0.36% | $24.3B | 915-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSSGY's Key Strengths?
Strong market position in bioprocessing and lab solutions.
- Comprehensive product portfolio and service offerings.
- Global presence and distribution network.
- Technological expertise and innovation capabilities.
What Are SSSGY's Weaknesses?
High P/E ratio may indicate overvaluation.
- Profit margin could be higher compared to industry leaders.
- Dependence on the biopharmaceutical industry.
What Could Drive SSSGY Stock Higher?
Increasing demand for biopharmaceuticals driving growth in bioprocessing solutions.
- Expansion of product portfolio through strategic acquisitions and innovation.
- Potential regulatory approvals for new biopharmaceutical products utilizing Sartorius's technologies.
- Growing adoption of single-use technologies in biomanufacturing.
- Development and launch of new data analytics platforms for bioprocessing.
What Are the Key Risks for SSSGY?
Rich valuation — a P/E of 81.70 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Intense competition from established players in the bioprocessing and lab solutions market.
- Regulatory changes in the healthcare sector affecting biopharmaceutical manufacturing.
- Currency fluctuations impacting revenue and profitability.
- Economic downturns affecting the biopharmaceutical industry.
- Dependence on key customers and suppliers.
What Are the Growth Opportunities for SSSGY?
- Expansion into Emerging Markets: Sartorius AG has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America, where the demand for biopharmaceuticals and advanced laboratory technologies is growing rapidly. This expansion could involve establishing new sales offices, distribution networks, or manufacturing facilities. The market size for biopharmaceuticals in emerging markets is projected to reach $200 billion by 2028, presenting a significant growth opportunity for Sartorius. Timeline: Ongoing.
- Development of Innovative Bioprocessing Solutions: Investing in the development of innovative bioprocessing solutions, such as advanced bioreactors, filtration systems, and chromatography products, can drive growth for Sartorius AG. These solutions can improve bioprocessing efficiency, reduce costs, and enhance product quality. The market for bioprocessing technologies is expected to reach $30 billion by 2027, driven by the increasing demand for biopharmaceuticals. Timeline: Ongoing.
- Strategic Acquisitions: Sartorius AG can pursue strategic acquisitions to expand its product portfolio, enter new markets, or gain access to new technologies. Acquisitions can provide synergies and accelerate growth. The company has a history of successful acquisitions, such as the acquisition of Novasep's chromatography division in 2021. Timeline: Ongoing.
- Increased Focus on Data Analytics and Automation: The integration of data analytics and automation into bioprocessing workflows can improve efficiency, reduce costs, and enhance product quality. Sartorius AG can invest in the development of data analytics platforms and automation solutions to meet the growing demand for these technologies. The market for data analytics in biopharmaceutical manufacturing is projected to reach $5 billion by 2028. Timeline: Ongoing.
- Expansion of Service Offerings: Sartorius AG can expand its service offerings, such as bioprocess development, engineering, and validation services, to provide comprehensive solutions to its customers. These services can generate recurring revenue and strengthen customer relationships. The market for bioprocessing services is expected to reach $15 billion by 2027, driven by the increasing complexity of biopharmaceutical manufacturing. Timeline: Ongoing.
What Are SSSGY's Competitive Advantages?
- Strong brand reputation and established customer relationships.
- Extensive product portfolio and comprehensive solutions.
- Technological expertise and innovation capabilities.
- Global presence and distribution network.
What Does SSSGY Do?
Founded in 1870 and headquartered in Göttingen, Germany, Sartorius AG has evolved into a leading provider of bioprocess solutions and lab products and services. The company supports the biopharmaceutical industry and research laboratories worldwide, offering a comprehensive portfolio of products and services designed to optimize bioprocessing workflows and laboratory operations. Sartorius's offerings include biosensors and kits, compliance tools, systems software, and a range of bioreactors, from multi-parallel to single-use and stainless steel models. They also provide filtration equipment, membranes, chromatography products, and fluid management solutions. Sartorius serves a diverse range of industries, including life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. Its global presence and diverse product portfolio have solidified its position as a key player in the bioprocessing and lab solutions market, competing with companies like ALBBY and CHEOF.
What Products and Services Does SSSGY Offer?
- Provides biosensors and kits for bioprocess monitoring.
- Offers compliance tools and systems software for regulated industries.
- Develops and manufactures bioreactors for cell culture and microbial fermentation.
- Supplies membranes, filters, and filtration equipment for bioprocessing.
- Provides chromatography products for protein purification.
- Offers fluid management products for biopharmaceutical manufacturing.
- Develops process analytical technology and data analytics solutions.
- Provides services such as bioprocess development and validation.
How Does SSSGY Make Money?
- Sartorius AG generates revenue through the sale of bioprocess solutions and lab products.
- The company also generates revenue through service offerings, such as bioprocess development and validation.
- Recurring revenue is generated through the sale of consumables, such as filters and media.
- The company invests in research and development to develop innovative products and solutions.
What Industry Does SSSGY Operate In?
Sartorius AG operates within the rapidly growing bioprocessing and lab solutions market, driven by the increasing demand for biopharmaceuticals and advanced research technologies. The industry is characterized by intense competition, with key players like ALBBY and BDUUY vying for market share. Trends include the adoption of single-use technologies, automation, and data analytics to improve bioprocessing efficiency and reduce costs. The company's focus on innovation and strategic acquisitions positions it well to capitalize on these trends and maintain its competitive edge.
Who Are SSSGY's Key Customers?
- Biopharmaceutical companies involved in drug development and manufacturing.
- Life science research laboratories.
- Quality control and testing laboratories.
- Applied industries, such as food and beverage.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 51 |
| 2026-08-27 | 51 |
| 2026-08-31 | 51 |
| 2026-09-04 | 51 |
| 2026-09-08 | 51 |
| 2026-09-11 | 51 |
What changed?
The score has stayed at 51.
Over the same 19 days the stock moved +0.0%.
Sartorius AG (SSSGY) Valuation Context
Valued at $15.2B, SSSGY is classified as a large-cap stock.
SSSGY Revenue & Earnings Trend
In Q2 FY2026, SSSGY generated $1.08B in top-line revenue, marking a sequential increase of 1.4%. The company recorded net income of $77.7M, with diluted EPS of $0.22. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SSSGY averaged $0.17 in diluted EPS.
Company Profile
Sartorius AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Göttingen, DE. The company is led by CEO Michael Grosse. SSSGY has traded publicly since 2021.
Key Financial Metrics
Return on equity for Sartorius AG stands at 6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.8%, showing how much profit it generates from its asset base. SSSGY trades at a trailing price-to-earnings ratio of 81.70, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sartorius AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.39 places it in the grey zone, a middle ground that warrants monitoring.
SSSGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in bioprocessing and lab solutions.
- Comprehensive product portfolio and service offerings.
- Global presence and distribution network.
- Technological expertise and innovation capabilities.
Bear Case
- High P/E ratio may indicate overvaluation.
- Profit margin could be higher compared to industry leaders.
- Dependence on the biopharmaceutical industry.
- Potential: Intense competition from established players in the bioprocessing and lab solutions market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.08B | $78M | $0.22 |
| Q1 FY2026 | $1.06B | $66M | $0.20 |
| Q4 FY2025 | $1.07B | $35M | $0.10 |
| Q3 FY2025 | $976M | $51M | $0.15 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
SSSGY Latest News
No recent news available for SSSGY.
SSSGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SSSGY.
Price Targets
Wall Street price target analysis for SSSGY.
SSSGY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SSSGY; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Grosse
CEO
Michael Grosse serves as the CEO of Sartorius AG, leading a global workforce of 13,573 employees. His career spans various leadership roles in the technology and manufacturing sectors. He has a strong background in strategic management and operational excellence. His expertise lies in driving growth through innovation and market expansion, with a focus on customer-centric solutions. He brings extensive experience in leading multinational organizations and fostering a culture of collaboration and performance.
Track Record: Under Michael Grosse's leadership, Sartorius AG has experienced significant growth and expansion, marked by strategic acquisitions and increased market share. He has overseen the development and launch of innovative bioprocessing solutions, strengthening the company's competitive position. His tenure has been characterized by a focus on operational efficiency and customer satisfaction, contributing to improved financial performance and enhanced shareholder value.
Sartorius AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. SSSGY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without requiring the same level of regulatory compliance as listed stocks. This allows U.S. investors to invest in Sartorius AG more easily.
- Home Market Ticker: Frankfurt Stock Exchange (FWB), Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SSSG
SSSGY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier have minimal listing requirements and may not be required to provide audited financial statements. This tier is often associated with higher risk and less transparency compared to higher-tier OTCQX and OTCQB markets, or exchange-listed stocks.
- OTC Tier: OTC Other
- Limited liquidity can make it difficult to buy or sell shares at desired prices.
- Lack of transparency due to limited financial disclosures.
- Potential for price manipulation and fraud.
- Higher volatility compared to exchange-listed stocks.
- Regulatory risks associated with the OTC market.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor.
- Established business operations and track record.
- Membership in industry associations.
- Positive media coverage and analyst reports.
- Partnerships with reputable companies.
- Experienced management team.
Sartorius AG Healthcare Stock: Key Questions Answered
Is SSSGY a good stock?
Stock Expert AI does not rate SSSGY buy, sell or hold. Sartorius AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about SSSGY stock?
Analyst consensus on SSSGY stock is mixed, with some analysts highlighting the company's strong market position and growth potential, while others express concerns about its high valuation and competitive landscape.
What are the key factors to evaluate for SSSGY?
Evaluate SSSGY on fundamentals, analyst consensus, and risk factors. P/E: 81.70x vs the S&P 500's ~20-25x. Sartorius AG presents a notable research candidate within the bioprocessing and lab solutions sector. Not financial advice.
How frequently does SSSGY data refresh on this page?
SSSGY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven SSSGY's recent stock price performance?
Sartorius AG (SSSGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in bioprocessing and lab solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSSGY overvalued or undervalued right now?
Sartorius AG (SSSGY) trades at 81.70x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SSSGY?
Yes, most major brokerages offer fractional shares of Sartorius AG (SSSGY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SSSGY's earnings and financial reports?
Sartorius AG (SSSGY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SSSGY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
No publishable V2 score is available for this stock yet.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.